Long-Term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection
- Affiliated Author(s)
- 장병국
- Alternative Author(s)
- Jang, Byoung Kuk
- Journal Title
- Clinical Gastroenterology and Hepatology
- ISSN
- 1542-7714
- Issued Date
- 2019
- Abstract
- Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported. Here, we investigated the long-term outcomes of antiviral treatment in patients with advanced liver disease.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.